Allergan PLC.’s (NYSE:AGN) Buy Rating Reaffirmed at Mizuho
A number of other research firms have also commented on AGN. Citigroup Inc. reissued a focus list rating and issued a $261.27 price objective (up previously from $184.50) on shares of Allergan PLC. in a research note on Friday, April 21st. Deutsche Bank AG reissued a buy rating and issued a $273.00 price objective (up previously from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Goldman Sachs Group, Inc. (The) lowered Allergan PLC. from a buy rating to a neutral rating and set a $262.00 price objective on the stock. in a research note on Wednesday, May 10th. Royal Bank Of Canada boosted their price objective on Allergan PLC. from $279.00 to $284.00 and gave the stock an outperform rating in a research note on Wednesday, May 10th. Finally, Vetr lowered Allergan PLC. from a buy rating to a hold rating and set a $234.38 price objective on the stock. in a research note on Monday, June 19th. Seven analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Allergan PLC. has an average rating of Buy and an average price target of $273.99.
Shares of Allergan PLC. (NYSE:AGN) traded up 0.07% on Wednesday, hitting $250.36. The stock had a trading volume of 3,414,589 shares. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The company’s market cap is $84.09 billion. The firm has a 50 day moving average price of $245.21 and a 200-day moving average price of $237.12.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The business’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.35 earnings per share. Analysts anticipate that Allergan PLC. will post $16.08 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/03/allergan-plc-s-nyseagn-buy-rating-reaffirmed-at-mizuho.html.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.12%. Allergan PLC.’s payout ratio is 9.63%.
In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.36% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Beacon Financial Group acquired a new position in Allergan PLC. during the first quarter worth about $325,000. Atalanta Sosnoff Capital LLC acquired a new position in Allergan PLC. during the first quarter worth about $25,801,000. Triangle Securities Wealth Management boosted its position in Allergan PLC. by 8.9% in the first quarter. Triangle Securities Wealth Management now owns 2,043 shares of the company’s stock worth $488,000 after buying an additional 167 shares during the last quarter. First American Trust FSB acquired a new position in Allergan PLC. during the first quarter worth about $4,081,000. Finally, Burns J W & Co. Inc. NY acquired a new position in Allergan PLC. during the first quarter worth about $215,000. 84.66% of the stock is owned by hedge funds and other institutional investors.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.